BenzingaSeptember 21, 2026 at 2:48 AM NYLast Month

B of A Securities Upgrades Candel Therapeutics to Buy, Raises Price Target to $18

CADLCandel Therapeutics Inc

B of A Securities analyst Alec Stranahan upgrades Candel Therapeutics (NASDAQ:CADL) from Neutral to Buy and raises the price target from $12 to $18.

What This Story Means

Read the Full Story at the Source

The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga